GDC (Vismodegib) is an FDA-approved drug for the treatment of metastatic basal cell carcinoma, and it acts to inhibit the hedgehog pathway by antagonizing smoothened protein (Babacan et al., 2012). Here, SLC25A16 is linked to basal cell carcinoma.